Prosecution Insights
Last updated: November 12, 2026
Application No. 18/577,850

TRANSPOSON SYSTEM AND USES THEREOF

Non-Final OA §102§103§112
Filed
Jan 09, 2024
Priority
Jul 09, 2021 — RE 10-2021-0090133 +2 more
Examiner
YU, DELPHINUS DOU YI
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Neogentc Corp.
OA Round
1 (Non-Final)
38%
Grant Probability
At Risk
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
3 granted / 8 resolved
-22.5% vs TC avg
Strong +71% interview lift
Without
With
+71.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
41 currently pending
Career history
51
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status This action is written in response to applicant’s correspondence received on 08/25/2026. Claims 1, 3-6, 8, 10-14, 16-19, 21, 22, 24, and 30-33 are currently pending. Claims 16-19, 21, 22, 24, and 30-33 are withdrawn from prosecution as being drawn to nonelected subject matter. Accordingly, claims 1, 3-6, 8, and 10-14 are examined herein. The restriction requirement mailed on 07/07/2026 is still deemed proper. Applicant elected Group I with traverse in the reply filed on 08/25/2026. Election/Restrictions Applicant's election with traverse of Group I in the reply filed on 08/25/2026 is acknowledged. The traversal is on the ground that “Groups I-IV share, as a common essential element, not merely a gene expression construct, but the transposon vector defined in claim 1, which comprises specific 5' ITR and 3' ITR sequences … the transposon vector of claim 1 constitutes a common special technical feature that defines the contribution over the prior art and links the respective Groups so as to form a single general inventive concept” (Remarks, page 2). This is not found persuasive because Higgins (US11542528B2, priority to PRO 63/175,345, filed on 04/15/2021 and others with earlier priority dates) anticipates the transposon vector of claim 1 with its “specific 5' ITR and 3' ITR sequences”, see the office action under 35 U.S.C. §102 below. The requirement is still deemed proper and is therefore made FINAL. Claims 16-19, 21, 22, 24, and 30-33 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected Groups II-IV, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 08/25/2026. Information Disclosure Statement The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Acknowledgment is made of applicant's claim for foreign priority based on an application filed in REPUBLIC OF KOREA. This application is a 371 of PCT/KR2022/010075 filed on 07/11/2022, with priority to 10-2021-0090133 filed on 07/09/2021, and 10-2022-0085306 filed on 07/11/2022. Specification Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words in length. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, “The disclosure concerns,” “The disclosure defined by this invention,” “The disclosure describes,” etc. In addition, the form and legal phraseology often used in patent claims, such as “means” and “said,” should be avoided. A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). The use of the terms FACS Aria, ATCC, Maxcyte, Neon, TruStain, Opti-MEM, which are trade names or marks used in commerce, has been noted in this application. The terms should be accompanied by the generic terminology; furthermore the terms should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 13, it is noted that the claim recites “b) a nucleic acid molecule including a sequence encoding a transposase protein or transposase”. This language is considered to be indefinite because of 2 plausible interpretations: 1), component b) requires only nucleic acid molecule which includes a sequence encoding a transposase protein or transposase, wherein “transposase protein” and “transposase” are two alternative terms of referring to the same thing with one being redundant, or 2), component b) requires either a transposase, in a protein form, or a nucleic acid molecule including a sequence encoding a transposase protein, a nucleic acid form. It is noted that the specification states that “The present invention is also directed to providing a transposon system for delivering target DNA, which includes the transposon vector and a transposase (a protein or a nucleic acid molecule encoding the same)” (Page 2, 3rd¶), the claim language as written remains indefinite. It is recommended that the claim language be revised to “b) a transposase protein or a nucleic acid molecule including a sequence encoding a transposase protein” to be consistent with the specification, thus providing clear metes and bounds. The broadest reasonable interpretation (BRI) is applied to include both readings below. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 3-5, 8, 10-13 are rejected under 35 U.S.C. 102(2) as being anticipated by Higgins (US11542528 B2, priority to PRO 63/175,345, filed on 04/15/2021 and others with earlier priority dates). Regarding claims 1, 3, 4, Higgins teaches a transposon vector, comprising: a 5' ITR having a sequence of at least 71 consecutive nucleotides in the nucleotide sequence represented by SEQ ID NO: 1 (FIG. 14, SEQ ID NO: 341; see alignment below); and a 3' ITR having a sequence of at least 66 consecutive nucleotides in the nucleotide sequence represented by SEQ ID NO: 2 (FIG. 15, SEQ ID NO: 433; see alignment below). Higgins calls the 5’ ITR “left end” and the 3’ ITR “right end” (FIG. 1D) or “left ITR” and “right ITR” (FIGs. 8B; 16; 24B), or “5’TRE” and “3’TRE” (FIG. 23E). Query: Higgins SEQ ID NO: 341; Sbjct: Instant SEQ ID NO: 1 PNG media_image1.png 286 831 media_image1.png Greyscale Query: Higgins SEQ ID NO: 433; Sbjct: Instant SEQ ID NO: 2 PNG media_image2.png 364 827 media_image2.png Greyscale Given the sequence relationships of SEQ ID NOs: 5-8, and 5’-ACACTTGG-3’ relative to SEQ ID NO: 1, and the sequence relationships of SEQ ID NOs: 9-11, 13, 14 relative to SEQ ID NO: 2, see below, Higgins also teaches claimed limitations in claims 3 & 4. 5’ ITR sequence: SEQ ID NO: 1 ttaacacttg gattgcggga aacgagttaa gtcggctcgc gtgaattgcg cgtactccgc gggagccgtc ttaactcggt tcatatagat ttgcggtgga gtgcgggaaa cgtgtaaact cgggccgatt gtaactgcgt attaccaaat atttgtt SEQ ID NO: 5 (bold sequence within SEQ ID NO: 1) ttaacacttg gattgcggga aacgagttaa gtcggctcgc gtgaattgcg cgtactccgc gggagccgtc ttaactcggt tcatatagat ttgcggtgga gtgcgggaaa cgtgtaaact cgggccgatt gtaactgcgt attaccaaat atttgtt SEQ ID NO: 6 (bold sequence within SEQ ID NO: 1) ttaacacttg gattgcggga aacgagttaa gtcggctcgc gtgaattgcg cgtactccgc gggagccgtc ttaactcggt tcatatagat ttgcggtgga gtgcgggaaa cgtgtaaact cgggccgatt gtaactgcgt attaccaaat atttgtt SEQ ID NO: 7 (bold sequence within SEQ ID NO: 1) ttaacacttg gattgcggga aacgagttaa gtcggctcgc gtgaattgcg cgtactccgc gggagccgtc ttaactcggt tcatatagat ttgcggtgga gtgcgggaaa cgtgtaaact cgggccgatt gtaactgcgt attaccaaat atttgtt 5’-ACACTTGG-3’ (bold sequence within SEQ ID NO: 1) ttaacacttg gattgcggga aacgagttaa gtcggctcgc gtgaattgcg cgtactccgc gggagccgtc ttaactcggt tcatatagat ttgcggtgga gtgcgggaaa cgtgtaaact cgggccgatt gtaactgcgt attaccaaat atttgtt SEQ ID NO: 8 (bold sequence within SEQ ID NO: 1) ttaacacttg gattgcggga aacgagttaa gtcggctcgc gtgaattgcg cgtactccgc gggagccgtc ttaactcggt tcatatagat ttgcggtgga gtgcgggaaa cgtgtaaact cgggccgatt gtaactgcgt attaccaaat atttgtt 3’ ITR sequence: SEQ ID NO: 2 aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ggcgggaaat tcacccgaca ccgtagtgtt aa SEQ ID NO: 9 (bold sequence within SEQ ID NO: 2) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ggcgggaaat tcacccgaca ccgtagtgtt aa SEQ ID NO: 10 (bold sequence within SEQ ID NO: 2) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ggcgggaaat tcacccgaca ccgtagtgtt aa SEQ ID NO: 11 (bold sequence within SEQ ID NO: 2) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ggcgggaaat tcacccgaca ccgtagtgtt aa SEQ ID NO: 13 (bold sequence within SEQ ID NO: 2) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ggcgggaaat tcacccgaca ccgtagtgtt aa SEQ ID NO: 14 (bold sequence within SEQ ID NO: 2) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ggcgggaaat tcacccgaca ccgtagtgtt aa Regarding claim 5, Higgins teaches the claimed sequence orientations in the transposon vector in FIG. 16 and in another embodiment in FIG. 23E. Regarding claim 8, Higgins teaches GFP or TurboGFP, and neomycin resistance gene as representative reporter proteins coding sequence in the vector map shown in FIG. 16 and FIG. 23E. Regarding claim 10, Higgins teaches a DNA donor construct template used with Myotis lucifugus transposase comprising a CMV promoter, a GFP and a Neomycin/Kanamycin resistance gene as >1 target genes, a TK polyA signal, in addition to a 5’ ITR, i.e. left ITR and a 3’ ITR, i.e. a right ITR in the representative vector map in FIG. 16 (Col 11, lines 3-7). Regarding claim 11, Higgins teaches a circular plasmid as a representative transposon vector in map show in FIGs. 16 and 23E. Regarding claim 12, Higgins’ FIG. 16 shows a representative transposon vector with a 7820bp size, which is within the claimed range of 1,000 to 10,000 bp. Regarding claim 13, Higgins teaches a transposon system comprising: a) a donor vector shown in FIG. 8B, into which target DNA (optimized transgene ORF as shown in the vector map) is inserted; and b) a helper vector which comprises a nucleic acid molecule including a sequence encoding a transposase protein (optimized Myotis lucifugus transposase, MLT; Col 3, lines 5-6) shown in FIG. 8A. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 6 is rejected under 35 U.S.C. 103 as being unpatentable over Higgins (2021; see full citation above), in view of Livet (WO2019219947A1, published on 11/21/2019). Higgins’ teachings have been discussed above as applied to claims 1, 3-5, 8, 10-13. Higgins does not teach “The transposon vector of claim 1, wherein the transposon vector includes antisense DNA having a reverse complement sequence of the nucleotide sequence of the 3' ITR in the 5' to 3' direction downstream of the position where target DNA is inserted into the transposon vector, wherein the reverse complement sequence of the 3' ITR includes the nucleotide sequence represented by any one of SEQ ID NOs: 15 to 17”. As shown below in the sequence alignment, SEQ ID NOs: 15-17 corresponds to SEQ ID NOs: 9-11 as their respective reverse complement sequences. Reverse complementary sequences to the 3’ ITR sequences NOs: 9-11: SEQ ID NO: 15 (reverse complement of SEQ ID NO: 9) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt |||| |||||||||| |||||||||| |||||||||| 3’- TTGG ATTTATTAAC GGGCGCGGTA GAATATAAAA ggcgggaaat tcacccgaca ccgtagtgtt aa |||||||||| |||||||||| |||||||||| CCGCCCTTTA AGTGGGCTGT GGCATCACAA TT – 5’ SEQ ID NO: 16 (reverse complement of SEQ ID NO: 10) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt ||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| 3’- TTTGATTGA GACTAAAACG CGCCCTTTGG ATTTATTAAC GGGCGCGGTA GAATATAAAA ggcgggaaat tcacccgaca ccgtagtgtt aa |||||||||| |||||||||| |||||||||| CCGCCCTTTA AGTGGGCTGT GGCATCACAA TT – 5’ SEQ ID NO: 17 (reverse complement of SEQ ID NO: 11) aattatttat gtactgaata gataaaaaaa tgtctgtgat tgaataaatt ttcatttttt acacaagaaa ccgaaaattt catttcaatc gaacccatac ttcaaaagat ataggcattt 3’- GTGTTCTTT GGCTTTTAAA GTAAAGTTAG CTTGGGTATG AAGTTTTCTA TATCCGTAAA taaactaact ctgattttgc gcgggaaacc taaataattg cccgcgccat cttatatttt |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| ATTTGATTGA GACTAAAACG CGCCCTTTGG ATTTATTAAC GGGCGCGGTA GAATATAAAA ggcgggaaat tcacccgaca ccgtagtgtt aa |||||||||| |||||||||| |||||||||| CCGCCCTTTA AGTGGGCTGT GGCATCACAA TT – 5’ However, Livet (2019) teaches that the 3’ ITR sequence can be flipped for a 5’ [Wingdings font/0xE0] 3’ orientation with reverse complementary sequence (Figure 1A, right configuration, ID switch), i.e. an antisense orientation as an alternative, interchangement embodiment of a transposon vector (Page 15, lines 11-26), and explicitly teaches one preferred embodiment wherein “a 5' ITR and a 3' ITR of a DNA transposon, advantageously a cut and paste DNA transposon … one of said sequence is in the sense orientation, while the other is in the anti-sense orientation, with respect to the sequence of the promoter” (Page 15, lines 30-33). Livet teaches that the purpose of this design is to achieve transposition-dependent transgene expression. This arrangement can suppress expression while the vector remains episomal, thereby reducing potentially toxic or otherwise undesirable effects of transient expression, while allowing sustained expression after genomic integration and facilitating identification of successfully integrated cells (Page 2, lines 1-13, 32-33; Page 3, lines 31-34; Page 4, ¶1-4). It would have been obvious for persons of ordinary skill in the art (PHOSITAs) before the effective filing date to have modified the transposon vector designs of Higgins by inverting the 3’ ITR sequence, such that “the transposon vector includes antisense DNA having a reverse complement sequence of the nucleotide sequence of the 3' ITR in the 5' to 3' direction downstream of the position where target DNA is inserted into the transposon vector…”. Since Higgins’ transposon vector comprises a 3’ ITR with the sequence set forth in the claimed SEQ ID NO: 2, which comprises SEQ ID NOs: 9-11, such an inverted 3’ ITR would have comprised a 5’-> 3’ sequence that is complementary on the sense strand, thereby reading on any of the claimed antisense DNA sequence set forth in SEQ ID NO: 15-17, yet still satisfying the requirement of the independent claim 1, upon which claim 6 depends and incorporating the requirement, because SEQ ID NO: 2 is still comprised in the inverted 3’ ITR by being present in the antisense strand of the DNA double strand in the 3’ ITR. It would have merely amounted to a simple substitution of prior art elements based on known methods with predictable results. One would be motivated to do so because Livet teaches this arrangement as a preferred embodiment and that it prevents episomal expression of the transgene as the antisense orientation of the flipped 3’ ITR helps the modified transposon vector architecture to minimize uncontrolled transgene expression and may reduce toxicity (Livet, Page 4, lines 29-34). One would have reasonable expectations for success because Livet demonstrates precise control of integration-based transgene expression devoid of non-integrative episomal gene expression (Figure 1B). Claim 14 is rejected under 35 U.S.C. 103 as being unpatentable over Higgins (2021) as applied to claims 1, 3-6, 8, 10-13 above, and further in view of Mitra (Proc Natl Acad Sci U S A. 2013;110(1):234-9). PNG media_image3.png 853 883 media_image3.png Greyscale The teachings of Higgins (2021) have been discussed above. Despite teaching a transposase protein sequence that matches 571/572 (99% sequence identity) of the amino acids in the claimed protein sequence, Higgins does not teach a transposase protein that includes the amino acid sequence set forth in SEQ ID NO: 18. However, Mitra (2013) teaches a piggyBat protein sequence (Table S2; Page 235) identical to the claimed transposase sequence set forth in SEQ ID NO: 18, see alignment on the right. Although Higgins does incorporate Mitra in its entirety (Col 44, lines 61-64), this data is not relied upon in Higgins’ disclosure. Hence, Mitra serves as a secondary reference for this rejection. Higgins discloses a Myotis lucifugus transposase-derived transposon system employing a transposase and identifies Mitra (2013) among its cited references. The piggyBat transposase disclosed by Mitra is also derived from Myotis lucifugus. It would have been obvious to a PHOSITA before the effective filing date of the invention to have substituted Higgins’ engineered transposase with Mitra’s expressly disclosed piggyBat transposase sequence in Higgins’ transposon system because Mitra establishes that piggyBat is an active mammalian DNA transposon and demonstrates its utility for transposition in mammalian cells, including human cells (Page 234, Abstract, lines 11-15). The use of the known piggyBat transposase would therefore have been a predictable selection of a previously characterized transposase from the same species for use in a transposon-based gene-delivery system, with a reasonable expectation of success based on Mitra’s demonstrated transposition activity (Page 237, Figure 4). It would have merely amounted to simple substitution of prior art elements using known methods to achieve predictable results. One would have been motivated to do so because Higgins claims a transposon system comprising a nucleic acid encoding a transposase enzyme, wherein the transposase enzyme comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 (Claim 1), and the claimed sequence set forth in SEQ ID NO: 18 falls within this claimed variant range because a single amino acid mismatch out of 572 AA puts Mitra’s transposase sequence with a 99% sequence identity with SEQ ID NO: 2 of Higgins, i.e. these are considered interchangeable variants by Higgins. One would have reasonable expectations for success because these transposases are art-recognized variants of each other with the same origin of species and carrying out the same functions. Conclusion No claims are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delphinus D. Yu whose telephone number (571) 272-1576. The examiner can normally be reached Mon-Thr 7:30am to 4:30pm Fri 10am to 2pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil P Hammell can be reached on (571) 270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DELPHINUS DOU YI YU/Examiner, Art Unit 1636 /NEIL P HAMMELL/Supervisory Patent Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Jan 09, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778136
VIRULENCE FACTOR FSPL GENE FROM SUGARCANE POKKAH BOENG DISEASE AND USE THEREOF
3y 7m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
38%
Grant Probability
99%
With Interview (+71.4%)
Low
PTA Risk
Based on 8 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month